Gen-Os®

  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
  • Gen-Os
Case Reports
Publications
Videos
  • Tissue origin :
    Cortico-cancellous heterologous bone mix
  • Tissue collagen :
    Preserved
  • Physical form :
    Slightly radiopaque granules
  • Composition :
    100% granulated mix
  • Granulometry :
    250-1000 µm
    1000-2000 µm
  • Re-entry time :
    4/5 months, depending on grafting site characteristics
  • Packaging :
    Vial: 0.25 g, 0.5 g, 1.0 g, 2.0 g
  • Product codes :
    250-1000 µm
    M1052FS | 1 Vial | 0.25 g | Porcine
    M1052FE | 1 Vial | 0.25 g | Equine
    M1005FS | 1 Vial | 0.5 g | Porcine
    M1005FE | 1 Vial | 0.5 g | Equine
    M1010FS | 1 Vial | 1.0 g | Porcine
    M1010FE | 1 Vial | 1.0 g | Equine
    M1020FS | 1 Vial | 2.0 g | Porcine
    M1020FE | 1 Vial | 2.0 g | Equine
    1000-2000 µm
    M0210FS | 1 Vial | 1.0 g | Porcine
    M0220FS | 1 Vial | 2.0 g | Porcine
  • GMDN code : 46425
Characteristics
A natural replicate of autologous bone, Gen-Os® conserves the same intimate structures(1) (matrix and porous form) and presents highly osteoconductive properties(2,3).
It is biocompatible and bioavailable, as recognized by tests made according to the ISO 10993 method conducted at Eurofins Biolab.
Gen-Os® is gradually resorbable and provides support in bone neoformation helping to preserve the original graft shape and volume(4). Moreover, thanks to its collagen content, the product facilitates blood clotting and the subsequent invasion of repairing and regenerative cells, favouring restitutio ad integrum of missing bone. Because of its marked hydrophilia(5), it can function as a carrier for selected medications and drugs(6) and it is ideal to mix with GFs(7).
Handling
Gen-Os® must always be hydrated and thoroughly mixed with either a few drops of sterile physiological solution (or patient's blood) to activate its collagen matrix and to enhance its adhesivity or with TSV Gel to increase graft stability in not self-contained defects. If necessary, it can as well be mixed with the drug selected for surgery.
Clinical information
Gen-Os®, a cortico-cancellous bone mix, has been the first product developed with the Tecnoss® innovative biotechnology and, due to its universal use, still is today the most demanded from the market. Gen-Os® has been successfully used and documented for alveolar ridge preservation(8) in combination with Evolution membranes: the application of this biomaterial limits the alveolar ridge width reduction that would naturally occur with spontaneous healing, preserving thus the alveolar ridge volume and allowing a correct second stage implant placement(9).
Gen-Os® has been used for lateral access maxillary sinus lift(3) and dehiscence regeneration(10), always in association with Evolution membranes.
Gen-Os® has been documented in periodontal regeneration of deep infrabony defects(11). Due to its collagen content, once hydrated Gen-Os® becomes very sticky and hydrophilic(5): it combines therefore extremely well with blood and is very stable once applied into the grafting site. Its cortico-cancellous composition allows a progressive resorption of osteoclastic type, with in parallel a similar rate of new bone formation(2): these unique properties allow a very good graft volume preservation, a healthy and well vascularized new bony tissue and, ultimately, a successful implant rehabilitation. Gen-Os® is in fact able to boost vascularization: in vitro(12) assays proved an increase in the secretion of VEGF by periodontal ligament cells (PDL) in the presence of Gen-Os®, as well as an enhanced proliferation of endothelial cells.
Bibliography
1 FIGUEIREDO M, HENRIQUES J, MARTINS G, GUERRA F, JUDAS F, FIGUEIREDO H
PHYSICOCHEMICAL CHARACTERIZATION OF BIOMATERIALS COMMONLY USED IN DENTISTRY AS BONE SUBSTITUTES - COMPARISON WITH HUMAN BONE
J BIOMED MATER RES B APPL BIOMATER, 2010 FEB; 92(2):409-19

2 NANNMARK U, SENNERBY L
THE BONE TISSUE RESPONSES TO PREHYDRATED AND COLLAGENATED CORTICO-CANCELLOUS PORCINE BONE GRAFTS: A STUDY IN RABBIT MAXILLARY DEFECTS CLIN IMPLANT DENT RELAT RES, 2008 DEC;10(4):264-70

3 CASSETTA M, PERROTTI V, CALASSO S, PIATTELLI A, SINJARI B, IEZZI G
BONE FORMATION IN SINUS AUGMENTATION PROCEDURES USING AUTOLOGOUS BONE, PORCINE BONE, AND A 50 : 50 MIXTURE: A HUMAN CLINICAL AND HISTOLOGICAL EVALUATION AT 2 MONTHS
CLIN ORAL IMPLANTS RES, 2015 OCT;26(10):1180-4

4 CARDAROPOLI D, CARDAROPOLI G
PRESERVATION OF THE POSTEXTRACTION ALVEOLAR RIDGE: A CLINICAL AND HISTOLOGIC STUDY
INT J PERIODONTICS RESTORATIVE DENT, 2008 OCT; 28(5):469-77

5FIGUEIREDO A, COIMBRA P, CABRITA A, GUERRA F, FIGUEIREDO M
COMPARISON OF A XENOGENEIC AND AN ALLOPLASTIC MATERIAL USED IN DENTAL IMPLANTS IN TERMS OF PHYSICO-CHEMICAL CHARACTERISTICS AND IN VIVO INFLAMMATORY RESPONSE
MATER SCI ENG C MATER BIOL APPL, 2013 AUG 1;33(6):3506-13

6 FISCHER KR, STAVROPOULOS A, CALVO GUIRADO JL, SCHNEIDER D, FICKL S
INFLUENCE OF LOCAL ADMINISTRATION OF PAMIDRONATE ON EXTRACTION SOCKET HEALING - A HISTOMORPHOMETRIC PROOF-OF-PRINCIPLE PRE-CLINICAL IN VIVO EVALUATION
CLIN ORAL IMPLANTS RES, 2015 OCT;26(10):1135-42

7 MIJIRITSKY E, FERRONI L, GARDIN C, BRESSAN E, ZANETTE G, PIATTELLI A, ZAVAN B
PORCINE BONE SCAFFOLDS ADSORB GROWTH FACTORS SECRETED BY MSCS AND IMPROVE BONE TISSUE REPAIR
MATERIALS, 2017 SEP 8;10(9)

8 CHECCHI V, FELICE P, ZUCCHELLI G, BARAUSSE C, PIATTELLI M, PISTILLI R, GRANDI G, ESPOSITO M
WIDE DIAMETER IMMEDIATE POST-EXTRACTIVE IMPLANTS VS DELAYED PLACEMENT OF NORMAL-DIAMETER IMPLANTS IN PRESERVED SOCKETS IN THE MOLAR REGION: 1-YEAR POST-LOADING OUTCOME OF A RANDOMISED CONTROLLED TRIAL
EUR J ORAL IMPLANTOL, 2017;10(3):263-278

9 FESTA VM, ADDABBO F, LAINO L, FEMIANO F, RULLO
PORCINE-DERIVED XENOGRAFT COMBINED WITH A SOFT CORTICAL MEMBRANE VERSUS EXTRACTION ALONE FOR IMPLANT SITE DEVELOPMENT: A CLINICAL STUDY IN HUMANS CLIN IMPLANT DENT RELAT RES, 2013 OCT;15(5):707-13

10 CASSETTA M, RICCI L, IEZZI G, DELL'AQUILA D, PIATTELLI A, PERROTTI V
RESONANCE FREQUENCY ANALYSIS OF IMPLANTS INSERTED WITH A SIMULTANEOUS GRAFTING PROCEDURE: A 5-YEAR FOLLOW-UP STUDY IN MAN
INT J PERIODONTICS RESTORATIVE DENT, 2012 OCT;32(5):581-9

11 ESPOSITO M, GRUSOVIN MG, LAMBERT F, MATOS S, PIETRUSKA M, ROSSI R, SALHI L, BUTI J
THE EFFECTIVENESS OF A RESORBABLE BONE SUBSTITUTE WITH A RESORBABLE MEMBRANE IN THE TREATMENT OF PERIODONTAL INFRABONY DEFECT - A MULTICENTER RANDOMISED CONTROLLED TRIA
EUR J ORAL IMPLANTOL, 2015;8(3):233-244

12 ROMBOUTS C, JEANNEAU C, CAMILLERI J, LAURENT P, ABOUT I
CHARACTERIZATION AND ANGIOGENIC POTENTIAL OF XENOGENEIC BONE GRAFTING MATERIALS: ROLE OF PERIODONTAL LIGAMENT CELLS
DENT MATER J, 2016 DEC 1;35(6):900-907
© 2020 Copyright by Tecnoss Dental Srl. P.I. 08917490016 REA: TO – 1010057. All rights reserved. Web Site developed by DSI Design
Disclosure on personal data processing - Information for customers - Information for suppliers